How bankrupt Pa. drug firm Endo could earn $265 million on an ‘exceptionally powerful opioid’ it removed twice from market

in September. Pennsylvania Attorney General Josh Shapiro was one of the seven whose filing called the top executive pre-bankruptcy bonuses “excessive.”

In 1970, 309 “addict-patients” at the city-run Philadelphia General Hospital spoke about their drug abuse. One-in-five said they abused Numorphan at least once, according to the 1972 published report on the findings. In 1982, Endo’s then-owner DuPont withdrew Numorphan tablets from the market for “commercial reasons” and amid “anecdotal reports of abuse by injection,” according to a FDA review of oxymorphone’s regulatory history.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen